Number of HIV-1 founder variants determined by source partner infection

July 02, 2020

For people infected by HIV in the subset of cases involving several variants of the virus, and for which disease progression is usually faster, a new modeling study suggests the number of infection-initiating viral variants is primarily determined by how long the source partner has been infected. According to the results of this work, which uniquely accounts for the sexual partner from whom the infection was acquired, the risk for multiple-founder variant transfer during sexual HIV exposure is nearly doubled during the first three months of the source partner's infection. These insights into the genetics of transmissible HIV strains could be crucial to developing effective HIV vaccine strategies. Despite the high genetic diversity of viruses in individuals with HIV-1, sexual transmission of the disease often only results from the passing of a single "founder" variant, which initiates the recipient's infection. But for some individuals - roughly 25% - infections involve several founding variants, which causes cases that exhibit faster disease progression and poorer clinical outcomes. While some evidence suggests that both viral and recipient partner factors may play a role in this genetic bottleneck, many studies evaluating multiple-founding HIV variants often lack data concerning the sexual partner from whom the infection was acquired. As a result, little is known about the importance of the source partner in determining the diversity of potential founder variants during sexual HIV exposure. Christian Julian Villabona-Arenas and colleagues analyzed sequence data on 112 sexual pairs in which the direction of transmission and infection stage of the source partner were known and used the data to create a phylodynamic model of founder-variant transmission. The results demonstrated that source partners with acute HIV-1 infections (those infected less than 90 days) are twice as likely to transmit multiple founder strains than those in the chronic stage of infection (infection older than 90 days), regardless of their sexual risk group (i.e., heterosexual or men-who-have-sex-with-men). The findings are contrary to claims arguing that some sexual risk groups are, in themselves, more physiologically prone to higher numbers of transmissible variants than others, illustrating the need for clinical analysis of known transmission pairs when evaluating the effect of sexual risk groups in HIV-1 infection.

American Association for the Advancement of Science

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to